Market Overview

Dicerna to Report Second Quarter 2018 Financial Results and Host Conference Call on August 8, 2018


Pharmaceuticals, Inc.
(NASDAQ:DRNA), a leading developer of
investigational ribonucleic acid interference (RNAi) therapeutics, today
announced that the Company will release its second quarter 2018
financial results after market close on Wednesday, August 8, 2018.

Management will host a conference call at 4:30 p.m. ET that day to
discuss the Company's financial results and provide a general business
update. The conference call will be webcast live via the Internet and
will be available on the "Investors & Media" section of the Dicerna
The webcast will also be archived on the Company's website.

The call can also be accessed by dialing (855) 453-3834 or (484)
756-4306 (international) and referencing conference ID 6588739 prior to
the start of the call. After the conference call, a replay will be
available until August 15, 2018. To access the replay, please dial (855)
859-2056 or (404) 537-3406 and refer to conference ID 6588739.

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on
the discovery and development of innovative RNAi-based therapeutics for
the treatment of diseases involving the liver, including rare diseases,
viral infectious diseases, chronic liver diseases, and cardiovascular
diseases. The Company is leveraging its proprietary GalXC™ RNAi
technology platform to build a broad pipeline in these core therapeutic
areas, focusing on target genes where connections between a target gene
and diseases are well understood and documented. The Company intends to
discover, develop and commercialize novel therapeutics either on its own
or in collaboration with pharmaceutical partners. For more information,
please visit

View Comments and Join the Discussion!